Psychemedics competitors

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. He is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. He was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, He made more than 200 investments into more than 40 private and public companies. In 1999, He founded YesRx, an HIV-focused pharmacy business. He's advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. He is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Eric Dickson is a Faculty Member at Institute for Healthcare Improvement, Senior Associate Dean at University of Massachusetts Medical School, and President/CEO at Umass Memorial Health Care Inc. He has worked as Emergency Room Physician at Umass Memorial Health Care Inc; Dir:Emergency Medicine Research at University of Massachusetts, Lowell; and Interim COO at University of Iowa Hospitals & Clinics. Eric works or has worked as TRUSTEE at Worcester County Food Bank and TRUSTEE at Clinton Hospital. He studied at University of Massachusetts Medical School, Harvard TH Chan School of Public Health, and Merrimack College.

Bill Corl is a Chief Executive Officer at Omega Laboratories Inc and is based in Omega Laboratories Ltd.

Jesse Shefferman is a co-founder of Protara and has led the Company since its inception through the addition of two late-stage assets, the establishment of multiple late-stage development programs and its listing on NASDAQ in early 2020. Jesse has spent over twenty years in the biopharma industry holding several strategic leadership and financial roles. Prior to co-founding Protara, Jesse was Vice President and Head of Business Development at Retrophin Inc., a leading rare diseases company where Jesse was a member of the executive leadership team and executed a number of company-defining transactions. Prior to Retrophin, Jesse served as Director, Strategy and Business Development at Vertex Pharmaceuticals, Inc., where he focused on hepatology and rare disease programs. Jesse previously served as an investment banker with Barclays Capital and Lehman Brothers, where he focused on providing strategic and financial advice to the management teams and boards of directors of numerous biopharmaceutical companies. Jesse holds an MBA and Certificate in Health Sector Management from Duke University and a BA in Accounting from Gordon College.

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers. Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer). Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.